Login to Your Account



EUROPE NEWS
LONDON – Restructuring and reshaping of the pharma industry across the globe has resulted in significant fallout in terms of programs, redundant facilities and skills. At the same time there has been significant externalization of R&D.
DATA FROM 18 PATIENTS
DUBLIN – Bidding to become the second European firm to win a gene therapy approval, Glaxosmithkline plc filed a marketing authorization application with the EMA for GSK2696273, a treatment for severe combined immunodeficiency syndrome associated with ADA-SCID in patients for whom bone marrow transplants are not possible.

LONDON – Taking the EMA's advice on trial design is both voluntary and costly, but a new analysis shows that doing so vastly increases the likelihood of getting marketing approval.

More EUROPE Headlines

Cast Your Vote

Has biotech’s bubble burst?: